Singapore, June 30 -- Biobot Surgical, a Singapore-based medical technology company developing robotic-assisted systems for prostate cancer diagnosis and treatment, has secured S$20 million in its latest financing round led by ClavystBio in partnership with ZIG Ventures.

The funding will accelerate the adoption of its Mona Lisa platform - which integrates robotic needle guidance and MRI-ultrasound image fusion for targeted prostate biopsy and focal ablation workflows - across its international markets.

It will also help to establish a focused US beachhead strategy, expand its clinical and economic evidence base, and strengthen the commercial capabilities required for its next phase of growth.

Prostate cancer is one of the most common c...